Search

Purpose: The majority of young adults with Hodgkin lymphoma (HL) are cured, but chemotherapy-induced infertility can have profound psychosocial consequences. Providing data on parenthood rates and use of assisted reproductive techniques (ARTs) after contemporary HL treatment is important for patient counseling and survivorship care., Materials and Methods: All Danish patients with HL diagnosed during 2000-2015 at the ages 18-40 years who achieved remission after first-line therapy were included and matched on age, sex, and parenthood status to five random persons from the general population. Parenthood rates were defined as the rate of first live birth per 1,000 person years, starting 9 months after HL diagnosis. Nationwide birth and patient registers were used to capture parenthood outcomes and ARTs use., Results: A total of 793 HL survivors and 3,965 comparators were included (median follow-up 8.7 years). Similar parenthood rates were observed for male and female HL survivors when compared with matched comparators (56.2 v 57.1; P = .871 for males and 63.8 v 61.2; P = .672 for females). For male HL survivors, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) therapy was associated with lower parenthood rates as compared to the matched comparators (28.1 v 60.8; P = .020). Live birth after ARTs were more common for HL survivors than for comparators (males 21.6% v 6.3%; P < .001; females 13.6% v 5.5%; P = .001). There were no differences in gestational age, Apgar score, or newborn measurements between HL survivors and matched comparators., Conclusion: The parenthood rates for HL survivors who have not experienced relapse were generally similar to the general population. However, ARTs were used more often before the first live birth in HL survivors, which is relevant information when discussing possible long-term side effects and fertility-preserving treatment options., Competing Interests: Andreas K. ØvlisenTravel, Accommodations, Expenses: Pfizer, AbbVie Lasse H. JakobsenHonoraria: Takeda Sandra ElorantaResearch Funding: JanssenOther Relationship: Janssen Martin HutchingsConsulting or Advisory Role: Takeda, Roche, Genmab, JanssenResearch Funding: Celgene, Genmab, Roche, Takeda, Novartis, Janssen Henrik FrederiksenConsulting or Advisory Role: AbbVie, NovartisResearch Funding: AbbVie, Gilead SciencesTravel, Accommodations, Expenses: Roche, AbbVie Rasmus Bo Dahl-SørensenTravel, Accommodations, Expenses: Takeda Caroline E. WeibullResearch Funding: Janssen Ingrid GlimeliusSpeakers' Bureau: Jansen Cilag Karin E. SmedbyResearch Funding: Janssen-Cilag Christian Torp-PedersenResearch Funding: Bayer, Novo Nordisk Tarec C. El-GalalyEmployment: RocheConsulting or Advisory Role: RocheOther Relationship: RocheNo other potential conflicts of interest were reported.